Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OBS-2
- Development stage
- Preclinical
- Lead developer
- insitro
01
Overview
OBS-2 is a preclinical drug candidate currently under development by insitro for the treatment of obesity. As part of insitro's obesity program, the candidate was identified using the company's proprietary platform, which integrates machine learning with high-throughput cellular biology to discover novel therapeutic targets. While the specific molecular modality and biological target for OBS-2 have not been publicly disclosed, the program focuses on addressing the complex genetic and cellular drivers of metabolic disease. The asset is part of a broader pipeline that leverages predictive models of human disease to accelerate drug discovery.
Beyond the preview
Go deeper on OBS-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OBS-2.